BlackRock Advisors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

BlackRock Advisors’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$367K	Buy	4,627 +117	+3%	+$8.5K	﹤0.01%	2396
2016 Q3	$316K	Sell	4,510 -5,555	-55%	-$308K	﹤0.01%	2419
2016 Q2	$390K	Sell	10,065 -6,635	-40%	-$276K	﹤0.01%	2251
2016 Q1	$676K	Buy	16,700 +291	+2%	+$18.5K	﹤0.01%	1941
2015 Q4	$1.46M	Sell	16,409 -12,377	-43%	-$977K	﹤0.01%	1544
2015 Q3	$2.13M	Sell	28,786 -1,482	-5%	-$123K	﹤0.01%	1339
2015 Q2	$2.45M	Buy	+30,268	New	+$1.97M	﹤0.01%	1188
2014 Q3	–	Sell	-1,570	Closed	-$22K	–	3725
2014 Q2	$22K	Buy	1,570 +208	+15%	+$2.37K	﹤0.01%	3427
2014 Q1	$17K	Buy	+1,362	New	+$18.5K	﹤0.01%	3448

Other funds holding EGRX

PAI

ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

BlackRock Advisors's EGRX Position: Q4 2016 in Review

BlackRock Advisors increased its Eagle Pharmaceuticals, Inc. (EGRX) stake by 2.6% in Q4 2016, buying an estimated $8.5K and bringing the position to 4,627 shares worth $367K. The position accounts for ﹤0.01% of the portfolio, ranked #2396.

BlackRock Advisors first reported a position in EGRX in Q1 2014 and has held it in 9 quarters since. The position peaked at $2.45M in Q2 2015. 149 funds tracked by Wall St. Rank hold EGRX as of Q4 2016.

BlackRock Advisors held 4,627 shares of Eagle Pharmaceuticals, Inc. worth $367K as of Q4 2016.
BlackRock Advisors bought 117 Eagle Pharmaceuticals, Inc. shares in Q4 2016, an estimated $8.5K.
Eagle Pharmaceuticals, Inc. made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #2396 holding.
BlackRock Advisors first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2014 and has held it in 9 quarters since.
BlackRock Advisors's Eagle Pharmaceuticals, Inc. position peaked at $2.45M in Q2 2015.
149 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.